One administration, with identical support
Participants received a single administration of psilocybin or a placebo in a trial described as randomized and double-blind. Both groups received the same psychological support. The comparison therefore concerns adding psilocybin to this support, not taking it alone without supervision.
The researchers assessed depressive symptoms using the Beck and Montgomery-Åsberg scales, along with self-concept—how a person sees and evaluates themselves. A task performed during functional MRI also explored processes related to self-focused attention.
Two associated improvements, with no established causality
Two weeks after administration, the psilocybin group showed a statistically significant reduction in depressive symptoms and an improvement in self-concept compared with placebo. Changes in self-concept were correlated with decreasing depression scores.
This association supports a line of research, but does not establish that better self-perception explains the effect on symptoms. The abstract provides neither numerical estimates of the differences between groups nor their uncertainty. It therefore does not allow a precise assessment of the benefit's clinical significance.
Imaging offers a clue, not a complete explanation
MRI showed a modulation of caudate nucleus activation during externally directed attention in the psilocybin group. In the placebo group, changes involved the processing of self-related information.
These findings suggest that the two groups changed differently on this task. However, they do not demonstrate that the observed brain changes cause the improvement in depression.
What this trial tells us
The value of this study lies in bringing together symptoms, self-perception and brain activity in a single controlled comparison. However, its small sample and results reported at two weeks limit conclusions about reproducibility and how long the effects last. These observations do not constitute a protocol for personal use.
Limitations to keep in mind
Only the PubMed abstract was consulted, not the full text. The analysis covers 37 people. The abstract does not detail effect sizes, adverse effects, whether blinding was maintained, or outcomes beyond two weeks. Funding and conflicts of interest were not checked.
What we can take away
With identical psychological support, psilocybin appears to improve depressive symptoms and self-perception at two weeks in this small trial. The causal role of self-perception remains to be established.
Sources and provenance
- Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patients.
Source date: 2026-11-10.
Journal Article, Randomized Controlled Trial · Résumé PubMed uniquement, texte intégral non consulté


